← Leaderboards
Erwin G Van Meir
University Of Alabama At Birmingham
$28,591,922
Attributed
$30,501,882
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,501,882 · 16
By mechanism
R01$19,363,402 · 10
P30$10,567,751 · 5
R21$570,729 · 1
Top collaborators
- Hans E Grossniklaus10 shared
- Binghe Wang3 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsTumor GrowthMalignant NeoplasmsSignal TransductionMolecularGrowthNovel TherapeuticsGliomaSignal PathwayPathway InteractionsIn VivoLeadNeoplastic CellBaseProgramsMediatingAngiogenesisCancer CellPropertyRadiation TherapyIn VitroChemotherapyReceptor
Grant awards (90)
Targeting MBD2 for medulloblastoma therapy$564,045
R01 · FY2025 · NS · contact PI
Shared Resource Management$457,959
P30 · FY2025 · CA · contact PI
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.$98,148
R01 · FY2025 · NS · contact PI
Shared Resource Management$2,821,396
P30 · FY2024 · CA · contact PI
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.$429,640
R01 · FY2024 · NS · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$403,819
R01 · FY2024 · CA · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$62,877
R01 · FY2024 · CA · contact PI
Shared Resource Management$2,821,399
P30 · FY2023 · CA · contact PI
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.$471,248
R01 · FY2023 · NS · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$416,571
R01 · FY2023 · CA · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$64,864
R01 · FY2023 · CA · contact PI
Shared Resource Management$2,821,399
P30 · FY2022 · CA · contact PI
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.$442,928
R01 · FY2022 · NS · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$416,571
R01 · FY2022 · CA · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$26,023
R01 · FY2022 · CA · contact PI
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.$442,928
R01 · FY2021 · NS · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$425,072
R01 · FY2021 · CA · contact PI
Cancer Cell Biology$82,644
P30 · FY2021 · CA · contact PI
Targeting Mechanisms of Medulloblastoma Formation$367,881
R01 · FY2020 · NS · contact PI
Cancer Cell Biology$82,644
P30 · FY2020 · CA · contact PI
Cancer Cell Biology$59,999
P30 · FY2020 · CA · contact PI
Cancer Cell Biology$49,527
P30 · FY2020 · CA · contact PI
Cancer Cell Biology$500,000
P30 · FY2019 · CA · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$425,072
R01 · FY2019 · CA · contact PI
Targeting mechanisms of medulloblastoma formation$386,460
R01 · FY2019 · NS · contact PI
Cancer Cell Biology$82,644
P30 · FY2019 · CA · contact PI
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma$21,469
R01 · FY2019 · CA · contact PI
Targeting mechanisms of medulloblastoma formation$386,460
R01 · FY2018 · NS · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$323,700
R01 · FY2018 · CA
Cancer Cell Biology$234,000
P30 · FY2018 · CA · contact PI
Cancer Cell Biology$82,644
P30 · FY2018 · CA · contact PI
Cancer Cell Biology$13,365
P30 · FY2018 · CA · contact PI
Cancer Cell Biology$4,861
P30 · FY2018 · CA · contact PI
Targeting mechanisms of medulloblastoma formation$386,460
R01 · FY2017 · NS · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$323,700
R01 · FY2017 · CA
Defining mechanisms of extracellular communication for cancer therapy$323,700
R01 · FY2017 · CA · contact PI
Cancer Cell Biology$50,360
P30 · FY2017 · CA · contact PI
Defining mechanisms of extracellular communication for cancer therapy$11,310
R01 · FY2017 · CA · contact PI
Targeting mechanisms of medulloblastoma formation$386,460
R01 · FY2016 · NS · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$323,700
R01 · FY2016 · CA
Defining mechanisms of extracellular communication for cancer therapy$323,700
R01 · FY2016 · CA · contact PI
Defining mechanisms of extracellular communication for cancer therapy$51,271
R01 · FY2016 · CA · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$48,411
R01 · FY2016 · CA
CANCER CELL BIOLOGY$34,078
P30 · FY2016 · CA · contact PI
Defining mechanisms of extracellular communication for cancer therapy$7,410
R01 · FY2016 · CA · contact PI
Discovery of chemical probes for uveal melanoma$564,926
R01 · FY2015 · CA · contact PI
Defining mechanisms of extracellular communication for cancer therapy$323,700
R01 · FY2015 · CA · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$323,700
R01 · FY2015 · CA
Defining mechanisms of extracellular communication for cancer therapy$49,361
R01 · FY2015 · CA · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$48,411
R01 · FY2015 · CA
CANCER CELL BIOLOGY$34,078
P30 · FY2015 · CA · contact PI
Discovery of chemical probes for uveal melanoma$558,016
R01 · FY2014 · CA · contact PI
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis$323,700
R01 · FY2014 · CA
Defining mechanisms of extracellular communication for cancer therapy$313,989
R01 · FY2014 · CA · contact PI
CANCER CELL BIOLOGY$31,255
P30 · FY2014 · CA · contact PI
Discovery of chemical probes for uveal melanoma$455,506
R01 · FY2013 · CA · contact PI
Defining mechanisms of extracellular communication for cancer therapy$323,700
R01 · FY2013 · CA · contact PI
CANCER CELL BIOLOGY$27,978
P30 · FY2013 · CA · contact PI
CANCER CELL BIOLOGY$2,340
P30 · FY2013 · CA · contact PI
CANCER CELL BIOLOGY$30,206
P30 · FY2012 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$427,765
R01 · FY2011 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$340,601
R01 · FY2011 · CA · contact PI
MOLECULAR PATHWAYS AND BIOMARKERS (MPB)$76,081
P30 · FY2011 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$538,885
R01 · FY2010 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$316,022
R01 · FY2010 · CA · contact PI
MOLECULAR PATHWAYS AND BIOMARKERS (MPB)$87,075
P30 · FY2010 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$522,611
R01 · FY2009 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$351,135
R01 · FY2009 · CA · contact PI
MOLECULAR PATHWAYS AND BIOMARKERS (MPB)$79,819
P30 · FY2009 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$45,141
R01 · FY2009 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$40,460
R01 · FY2009 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$519,285
R01 · FY2008 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$318,638
R01 · FY2008 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$40,460
R01 · FY2008 · CA · contact PI
Targeting Glioblastoma Using Novel Small Molecule HIF-1 Pathway Inhibitors$418,019
R01 · FY2007 · CA · contact PI
Therapeutic modulation of angiogenesis in human gliomas$351,135
R01 · FY2007 · CA · contact PI
A hypoxia-dependent adenovirus for glioma therapy$335,423
R01 · FY2005 · CA
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$527,139
R01 · FY2004 · CA
A hypoxia-dependent adenovirus for glioma therapy$335,423
R01 · FY2004 · CA
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$477,178
R01 · FY2003 · CA
A hypoxia-dependent adenovirus for glioma therapy$335,423
R01 · FY2003 · CA
Hypoxia as a target for the treatment of brain tumors$190,000
R21 · FY2003 · NS
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$69,079
R01 · FY2003 · CA
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$337,320
R01 · FY2002 · CA
A hypoxia-dependent adenovirus for glioma therapy$333,572
R01 · FY2002 · CA
Hypoxia as a target for the treatment of brain tumors$190,000
R21 · FY2002 · NS
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$57,631
R01 · FY2002 · CA
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$338,220
R01 · FY2001 · CA
Hypoxia as a target for the treatment of brain tumors$190,729
R21 · FY2001 · NS
THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS$339,930
R01 · FY2000 · CA